Over the past decade, a number of new therapies have been approved for the treatment of renal cell carcinoma (RCC; Figure 1). Most treatments are driven by clear cell histology, which represents 70% to 75% of all RCCs. Eric Jonasch, MD, Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Guidelines Panel, reviewed the state of the art and new systemic therapies incorporated into the 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Kidney Cancer.
Dr. Jonasch has disclosed that he has received consulting fees and honoraria from Bristol-Myers Squibb Company, Eisai Inc., Exelixis Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Laboratories, Inc., and grant/research support from Exelixis Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Hass NB, Manola J, Uzzo RG. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomized, phase 3 trial. Lancet 2016;387:2008–2016.
Ravaud A, Motzer RJ, Pandha HS. Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246–2254.
Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356:115–124.
Sternberg C, Davis ID, Mardiak J. Pazopanib in locally advanced metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–1068.
Hudes G, Carducci M & Tomczak P Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007;356:2271–2281.
Choueiri TK, Halabi S, Sanford BL. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591–597.
Motzer RJ, Escudier B, McDermott DF. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015;373:1803–1813.
Choueiri T, Powles T, Escudier BJ. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 4506.
Motzer RJ, Hutson TE & Ren M Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17:e4–5.
Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.